Kovo Completes Shares for Debt Transaction
Kovo Completes Shares for Debt Transaction
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Kovo Healthtech Corporation (TSXV: KOVO) ("Kovo" or the "Corporation") is pleased to announce that, further to its news release dated May 20, 2024, the TSX Venture Exchange (the "TSXV") has approved the Corporation's previously announced debt conversion transaction (the "Debt Conversion Transaction") and the Corporation settled outstanding debt in the aggregate amount CDN$2,257,229.56 owing to its largest secured creditor, Avonlea Ventures #2 Inc. ("AVI") by issuing 57,543,906 common shares in the capital of the Corporation ("Common Shares") at a deemed issue price per Common Share equal to $0.035 and 4,863,861 Common Shares at a deemed issue price per Common Share equal to $0.05. In aggregate, 62,407,767 Common Shares (the "Settlement Shares") were issued to AVI and are subject to a customary four month plus one day hold period.
温哥华,不列颠哥伦比亚省--(新闻稿社 - 2024年7月24日) -Kovo Healthtech Corporation (TSXV: KOVO) (以下简称“Kovo”或“公司”)很高兴地宣布,根据2024年5月20日发布的新闻稿,TSX Venture Exchange(以下简称“TSXV”)已核准公司此前宣布的债务转换交易(以下简称“债务转换交易”),并通过以$0.035发行57,543,906股公司(“普通股”)和以$0.05发行4,863,861股公司的价格偿还其最大的有担保债权人Avonlea Ventures#2 Inc.(“AVI”)所拖欠的总额为CDN$2,257,229.56的欠款。总计发行了62,407,767股普通股(以下简称“和解股份”)给AVI,受到惯常的四个月加一天的冻结期的限制。
Upon the TSXV acceptance of the Debt Conversion Transaction: (i) the forbearance agreement dated February 27, 2024 between Kovo and AVI terminated and the Corporation is no longer subject to the default interest rate provided for in the senior loan and security agreement dated as of April 20, 2023 (the "Loan Agreement"); and (ii) the amendment and restatement of the Loan Agreement (the "Amended and Restated Loan Agreement") is deemed effective and, among other things, extends the maturity date of the remaining indebtedness owed to AVI (the "Remaining Indebtedness") to April 30, 2025 and provides AVI with the right to convert the Remaining Indebtedness into Common Shares (the "Additional Conversion Right") at a fixed price of CDN$0.05 per share (the "Loan Agreement Amendments", with the Debt Conversion Transaction and the Loan Agreement Amendments collectively, the "Transaction"). As a condition to obtaining the TSXV acceptance, the Corporation and AVI filed undertakings with the TSXV confirming that: (i) Kovo has not and will not make any adjustments to the outstanding equity incentive awards issued under the Corporation's equity incentive plan as a consequence of or in respect of the Transaction; and (ii) AVI shall not exercise its Additional Conversion Right unless, after such conversion, Kovo continues to meet the applicable Continued Listing Requirements in accordance with the policies of the TSXV.
在TSXV接受债务转换交易后:(i) 2024年2月27日Kovo与AVI的自我克制协议终止,公司不再受制于自2023年4月20日《贷款协议》中提供的违约利率;和(ii)贷款协议的修正和重签(“修订贷款协议”)被视为生效,并且在其他事项中将应对其所欠AVI的尚未偿还债务(“剩余欠款”)的到期日延长至2025年4月30日,并向AVI提供在每股CDN$0.05的固定价格上将剩余欠款转换为普通股的权利(“其他转换权”)(“贷款协议修订”,包括债务转换交易和贷款协议修订在内,均称为“交易”)。作为获得TSXV接受的条件,公司和AVI向TSXV提交承诺,确认:(i) Kovo未且不会由于交易而对公司的权益激励计划下已发行的未解决的股权激励奖励进行任何调整;和(ii)除非在符合TSXV政策中的适用持续上市要求的情况下,否则AVI不得行使其其他转换权。
About Kovo HealthTech Corporation
Kovo HealthTech Corporation简介
Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit .
Kovo HealthTech Corporatio是一家快速增长的医疗技术公司,专门提供SaaS样式的医疗账单管理服务,为2250多家美国医疗机构提供软件服务。Kovo帮助医疗服务提供商以无缝的方式处理和管理繁琐的患者护理登记、服务、账单和支付。目前,通过其客户,Kovo每年为超过350万患者处理超过2.5亿加元(2亿美元)的年度账单交易。通过提供有效的账单实践,Kovo帮助医疗从业者得到报酬,以便他们可以专注于提供优质的医疗保健服务。有关Kovo的更多信息以及Kovo新闻的最新动态,请访问 。
For more information:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777
欲了解更多信息:
Kovo董事长
investors@kovo.co
1-866-558-6777
Forward Looking Information
前瞻性信息
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Corporation's settlement of certain debt obligations owed to entities controlled by a current directors of the Corporation, the future financial condition of the Corporation and its prospects, including any proposed debt restructuring transaction, including the Debt Conversion Transaction and the Loan Agreement Amendments. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
本新闻发布含有股份法适用范围内的前瞻性声明及前瞻性信息。这些声明和信息是关于未来事件或未来表现的。除了历史事实陈述的声明之外,所有陈述都可能是前瞻性声明或信息。更为具体地且不受限制地,本新闻发布包含有关公司结算欠某现任董事所控制公司的某些债务,公司未来财政状况及其前景,包括任何拟议的债务重组业务的前瞻性声明和信息,包括债务转换交易和贷款协议修正。前瞻性声明和信息基于公司管理层作出的某些关键预期和假设。尽管公司管理层相信前瞻性声明和信息基于合理的预期和假设,但不应过度依赖前瞻性声明和信息,因为无法保证它们会被证明是正确的。
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Corporation's ability to continue operations without adequate capital, the Corporation's ability to raise further capital, the Corporation's ability to meet the terms of its current debt obligations and to repay its indebtedness with or without the Debt Conversion Transaction and the Loan Agreement Amendments, the likelihood of the Corporation satisfying its ongoing obligations under the proposed Debt Conversion Transaction and Loan Agreement Amendments, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties, and the likelihood of any debt restructuring transaction being consummated, and the Corporation not defaulting in the future. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
提供前瞻性陈述和信息是为了提供有关公司管理层有关未来的当前预期和计划的信息。读者应注意,依赖此类陈述和信息可能不适用于其他目的,例如做出投资决策。由于前瞻性陈述和信息涉及未来事件和条件,因其本质而言,它们涉及固有的风险和不确定性。由于多种因素和风险,实际结果可能会与目前预期有所不同。这些因素和风险包括但不限于,公司无法在没有充足资本的情况下继续运营,公司无法筹集进一步资本,公司无法履行其当前债务义务并在有或无债务转换交易及贷款协议修正的情况下偿还其负债,公司满足拟议债务转换交易和贷款协议修正的持续义务的可能性,公司成功高效地开发新机会的能力,未能确定未来交易交易对手,债务重组交易可能达成的可能性,以及公司未来不违约的可能性。因此,读者不应过分依赖本新闻稿中包含的前瞻性陈述和信息。读者应注意,上述因素列表并非详尽无遗。本新闻稿中包含的前瞻性陈述和信息是截至本日作出的,恕不承诺公开更新或修订任何前瞻性陈述或信息,除非适用的证券法律要求如此。本新闻稿中包含的前瞻性陈述或信息明确受到此警示性声明的限制。